Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

24.12
+1.727.68%
Post-market: 24.120.00000.00%19:09 EDT
Volume:938.68K
Turnover:22.47M
Market Cap:1.57B
PE:-8.09
High:24.93
Open:22.49
Low:22.05
Close:22.40
Loading ...

Kymera Therapeutics (KYMR) Gets a Hold from Wells Fargo

TIPRANKS
·
25 Nov 2024

U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix

Reuters
·
19 Nov 2024

Kymera Therapeutics Initiated at Overweight by Stephens & Co.

Dow Jones
·
18 Nov 2024

Kymera Therapeutics initiated with an Overweight at Stephens

TIPRANKS
·
18 Nov 2024

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)

TIPRANKS
·
05 Nov 2024

Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)

TIPRANKS
·
05 Nov 2024

Kymera Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
05 Nov 2024

UBS Adjusts Price Target on Kymera Therapeutics to $74 From $80, Maintains Buy Rating

MT Newswires Live
·
04 Nov 2024

Kymera Therapeutics Price Target Cut to $53.00/Share From $54.00 by Truist Securities

Dow Jones
·
01 Nov 2024

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

Zacks
·
01 Nov 2024

Kymera Therapeutics price target raised to $52 from $45 at Guggenheim

TIPRANKS
·
01 Nov 2024

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber

Reuters
·
01 Nov 2024

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com
·
01 Nov 2024

Kymera Therapeutics Inc : Truist Securities Cuts Target Price to $53 From $54

THOMSON REUTERS
·
01 Nov 2024

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift

TIPRANKS
·
01 Nov 2024

Kymera Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Dow Jones
·
01 Nov 2024

Stock Track | Kymera Therapeutics Plunges on Q3 Revenue Miss and Strategic Pivot

Stock Track
·
01 Nov 2024

Kymera Therapeutics: Strategic Focus and Promising Trials Justify Buy Rating

TIPRANKS
·
01 Nov 2024

Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating

MT Newswires Live
·
01 Nov 2024